The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADAP | -92.71% | -98.87% | -59.21% | -100% |
| S&P | +17.35% | +108.64% | +15.84% | +227% |
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.84M | -89.2% |
| Gross Profit | $8.77M | -93.0% |
| Gross Margin | 63.37% | -34.5% |
| Market Cap | $61.81M | -75.2% |
| Market Cap / Employee | $0.12M | 0.0% |
| Employees | 506 | 12.7% |
| Net Income | -$30.70M | -144.1% |
| EBITDA | -$30.23M | -143.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.06M | -87.7% |
| Accounts Receivable | $9.31M | 298.8% |
| Inventory | 11.4 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.17M | 5.0% |
| Short Term Debt | $4.51M | -14.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -75.07% | -53.2% |
| Return On Invested Capital | -109.32% | 1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$35.48M | -175.5% |
| Operating Free Cash Flow | -$35.40M | -174.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.52 | 1.72 | 4.25 | -1.65 | -116.16% |
| Price to Sales | 1.38 | 0.77 | 0.28 | 0.96 | -46.13% |
| Price to Tangible Book Value | 2.55 | 1.82 | 6.33 | -1.50 | -114.35% |
| Enterprise Value to EBITDA | -9.01 | -1.07 | -0.92 | -2.84 | -328.84% |
| Return on Equity | -65.1% | -53.5% | -273.4% | -1341.4% | 343.77% |
| Total Debt | $74.50M | $74.21M | $48.71M | $48.68M | 2.81% |
ADAP earnings call for the period ending September 30, 2021.
ADAP earnings call for the period ending June 30, 2021.
ADAP earnings call for the period ending September 30, 2020.
ADAP earnings call for the period ending June 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
